A Phase I Study of Pomalidomide and Nivolumab in Patients With Virus-Associated Malignancies With or Without HIV

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Nivolumab (Primary) ; Pomalidomide (Primary) ; Aspirin
Indications Anal cancer; Cervical cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Kaposi's sarcoma; Leiomyosarcoma; Liver cancer; Lymphoma; Merkel cell carcinoma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Penile cancer; Primary-Effusion-Lymphoma; Vulvovaginal cancer
Focus Adverse reactions

28 Oct 2024 Planned number of patients changed from 54 to 64.
10 Dec 2021 Planned initiation date (estimated date for recruitment of the first subject) changed to 16 Dec 2021.
26 Nov 2021 Planned initiation date (estimated date for recruitment of the first subject) changed from 30 Nov 2021 to 2 Dec 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com